Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction

BACKGROUND: Trastuzumab is life‐extending therapy for breast cancer patients overexpressing the human epidermal growth factor receptor 2 (HER2+), but has known cardiotoxic risk. We sought to determine if trastuzumab can be administered to patients with reduced baseline cardiac function at no higher...

Descripción completa

Detalles Bibliográficos
Autores principales: Nowsheen, Somaira, Aziz, Khaled, Park, Jae Yoon, Lerman, Amir, Villarraga, Hector R., Ruddy, Kathryn Jean, Herrmann, Joerg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201446/
https://www.ncbi.nlm.nih.gov/pubmed/30371238
http://dx.doi.org/10.1161/JAHA.118.008637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201446/
https://www.ncbi.nlm.nih.gov/pubmed/30371238
http://dx.doi.org/10.1161/JAHA.118.008637

Ejemplares similares